Revolutionary Prevention Method
Gilead Sciences' lenacapavir, the world's only twice-a-year HIV prevention shot, has shown promise in nearly eliminating new infections among high-risk groups, surpassing the effectiveness of daily preventive pills.
The shot's six-month protection period makes it the longest-lasting preventive option available, potentially offering a more convenient alternative for those hesitant about daily pills or frequent doctor visits.
Challenges and Perspectives
Despite its potential, systemic issues in the U.S. and globally, including healthcare cuts and reduced foreign aid, pose significant challenges to the widespread adoption and accessibility of lenacapavir.
Studies in South Africa, Uganda, and the U.S. demonstrate the shot's effectiveness across diverse populations, including women and gay men, highlighting its potential to expand HIV prevention efforts.